Table 2 Clinical and biochemical parameters within the groups
Linagliptin Group | Voglibose Group | Control Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
Parameters | Baseline (n = 10) | 6 months (n = 10) | P value | Baseline (n = 9) | 6 months (n = 9) | P value | Baseline (n = 7) | 6 months (n = 7) | P value |
Weight (Kg) | 75.3 (69.2–85.3) | 73.4(66.3–84.3) | 0.066 | 60.7(55.4–71.5) | 56.8(53.5–67.7) | 0.208 | 74.0(58.7–84.4) | 75.3(57.9–82.4) | 0.612 |
BMI (kg/m2) | 25.5 (23.6–31.1) | 25.0(23.1–30.1) | 0.093 | 25.9(23.8–26.6) | 24.4(23.8–25.7) | 0.260 | 26.4(23.8–30.5) | 26.6(23.7–30.7) | 0.612 |
HbA1c (%) | 6.8 (6.4–7.1) | 6.6 (6.3–6.9) | 0.474 | 7.0(6.8–7.4) | 6.6 (6.5–6.6) | 0.015a | 7.0(6.8–7.1) | 7.0(6.8–7.4) | 0.491 |
Fasting Plasma Glucose (mmol/L) | 6.5(5.9–7.3) | 6.3(5.6–6.9) | 0.308 | 6.9(6.2–7.4) | 6.3(5.8–6.6) | 0.058 | 6.2(6.1–6.6) | 6.9(6.2–7.4) | 0.310 |
HOMA-IR | 2.0(1.9–2.3) | 1.7(1.1–2.1) | 0.169 | 1.6(1.3–2.0) | 1.7(1.2–1.9) | 0.678 | 2.4(1.7–3.3) | 0.128 | 0.128 |
HOMA-β (%) | 84.1(75.1–95.9) | 81.9(70.8–90.2) | 0.285 | 65.0(52.2–85.7) | 78.3(59.9–111.6) | 0.374 | 81.2(69.7–134.8) | 0.866 | 0.866 |
Mixed Meal Tolerance Test | |||||||||
AUC C-peptide (nmol/L) | 473.3(376.9–567.8) | 364.2(301.2–483.1) | 0.508 | 421.2(40.9.8–526.9) | 337.6(328.9–353.9) | 0.139 | 595.6(460.5–623.8) | 570.6(344.6–697.2) | 1.000 |
M0 ×10−8 (1/min) | − 0.4(− 2.6–0.8) | 2.1(− 0.6–3.3) | 0.203 | −0.5 (− 2.8–1.2) | 2.9(0.5–3.2) | 0.214 | − 2.6(− 5.9–1.2) | 0.1(− 3.7–4.3) | 0.176 |
M1 × 10− 8 (1/min) | 6.4(4.5–8.7) | 4.6(3.1–5.2) | 0.333 | 5.7(3.6–7.6) | 3.3(2.4–4.2) | 0.214 | 7.7(5.5–1.2) | 3.8(1.6–8.3) | 0.310 |
Hyperinsulinemic-Euglycemic Clamp Study | |||||||||
Glucose disposal rate (mg/Kg min) | 2.7(2.0–5.5) | 2.9(2.7–3.9) | 0.508 | 3.2(2.6–3.5) | 3.4(3.1–3.8) | 0.173 | 2.2(1.8–3.0) | 2.6(1.8–3.0) | 0.866 |
Insulin sensitivity (mg/(Kgmin)/μU/mL) | 4.4(2.5–8.0) | 4.0(3.4–5.9) | 0.878 | 5.3(3.6–6.7) | 5.6(5.2–6.1) | 0.859 | 3.2(2.3–5.1) | 3.4(2.4–4.8) | 0.866 |